B Group Inc. Takes Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

B Group Inc. purchased a new position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 965,556 shares of the company's stock, valued at approximately $1,670,000. Taysha Gene Therapies makes up about 1.0% of B Group Inc.'s portfolio, making the stock its 10th biggest holding. B Group Inc. owned 0.47% of Taysha Gene Therapies at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Geode Capital Management LLC lifted its holdings in Taysha Gene Therapies by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company's stock worth $6,182,000 after purchasing an additional 9,591 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Taysha Gene Therapies by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 474,257 shares of the company's stock valued at $820,000 after acquiring an additional 11,390 shares in the last quarter. Privium Fund Management B.V. grew its holdings in shares of Taysha Gene Therapies by 12.4% during the fourth quarter. Privium Fund Management B.V. now owns 134,900 shares of the company's stock worth $233,000 after purchasing an additional 14,900 shares during the last quarter. Cibc World Markets Corp bought a new stake in shares of Taysha Gene Therapies in the fourth quarter worth $28,000. Finally, E Fund Management Co. Ltd. acquired a new position in Taysha Gene Therapies during the 4th quarter worth about $31,000. 77.70% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on TSHA. Chardan Capital restated a "buy" rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. Needham & Company LLC restated a "buy" rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, April 10th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $6.63.

Taysha Gene Therapies Stock Down 3.3 %

Taysha Gene Therapies stock traded down $0.06 during midday trading on Friday, hitting $1.76. 1,698,834 shares of the stock were exchanged, compared to its average volume of 2,704,175. The stock has a market capitalization of $360.90 million, a price-to-earnings ratio of 2.79 and a beta of 0.96. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. The business's 50-day moving average price is $1.55 and its 200-day moving average price is $1.80. Taysha Gene Therapies, Inc. has a 52-week low of $1.05 and a 52-week high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The business had revenue of $2.02 million for the quarter, compared to analyst estimates of $2.05 million. On average, research analysts expect that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.